StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a report issued on Friday morning. The firm issued a sell rating on the medical research company’s stock.
Organovo Stock Up 2.6 %
NASDAQ:ONVO opened at $0.47 on Friday. The company’s 50-day moving average price is $0.52 and its two-hundred day moving average price is $0.75. Organovo has a 12 month low of $0.43 and a 12 month high of $2.05. The firm has a market cap of $7.23 million, a PE ratio of -0.34 and a beta of 0.61.
Organovo (NASDAQ:ONVO – Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.15. The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.03 million. On average, research analysts expect that Organovo will post -0.96 EPS for the current fiscal year.
Institutional Trading of Organovo
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Read More
- Five stocks we like better than Organovo
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Best Aerospace Stocks Investing
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- Quiet Period Expirations Explained
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.